Tatiana N. Moiseeva

Tatiana N. Moiseeva

Auto-generated profile, based on publicly available information

Tatiana N. Moiseeva

National Medical Research Center for Hematology

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
HJHunan Julhakyan
Hunan Julhakyan
LAL.S. Al-Radi
L.S. Al-Radi
TMT.N. Moiseeva
T.N. Moiseeva
KDK.I. Danishyan
K.I. Danishyan
AKAlla Mikhailovna Kovrigina
Alla Mikhailovna Kovrigina
VSV.G. Savchenko
V.G. Savchenko

28 June 2022 in Atherothrombosis
Verified
Journal Article
Open access
PDF file
SVS. A. Vasiliev
S. A. Vasiliev
LGL. A. Gorgidze
L. A. Gorgidze
EEE. E. Efremov
E. E. Efremov
GBG. Yu. Belinin
G. Yu. Belinin
TMT. N. Moiseeva
T. N. Moiseeva
AKA. V. Kokhno
A. V. Kokhno
Plasma fibronectin is a high molecular weight adhesive glycoprotein. There are two types of fibronectin: plasma (soluble) and cellular derived (insoluble). Electron microscopy revealed two types of structural organization of fibronectin: compact and expanded. In solution, fibronectin has a compact conformation, and after binding to certain substrates (collagen, fibrin, heparin), it is expanded. Plasma fibronectin is one of the main opsonins of blood plasma in relation to the “targets” of phagocytosis of a predominantly non-bacterial nature, as well as to some types of bacteria. For the treatment of septic processes, as well as respiratory distress syndrome of adults with severe fibronectin deficiency, plasma cryoprecipitate is used – a donor plasma preparation containing a large amount of plasma fibronectin (more than 2 mg/ml). It was proposed to replenish the level of fibronectin in patients with sepsis and other conditions that cause plasma fibronectin deficiency with the help of donor freshly frozen plasma. Transfusion of large volumes of freshly frozen plasma (up to 1000–1500 ml) to patients effectively eliminates the deficiency of plasma fibronectin. The concentration of plasma fibronectin in the blood significantly decreases after the addition of severe infectious processes to hematological diseases, as well as acute DIC syndrome. Extracorporeal methods of blood purification – selective plasmapheresis – have been developed to correct immunocomplex and fibronectin-complex pathology. Two variants of selective plasmapheresis have been proposed: the method of heparinocryoprecipitation of plasma proteins and the method of heparinocryofractionation. In 1987, a plasma heparin precipitate was proposed as a source of fibronectin for the treatment of patients with trophic skin lesions. In 1992, a new method was proposed for obtaining blood preparations with a high concentration of plasma fibronectin from patients themselves (heparin cryofractionation). Autofibronectin preparations obtained by such methods are effective in the local treatment of trophic ulcers in 90–93% of cases. The proposed drugs are safe against infection of patients with infectious diseases transmitted through the blood.

29 September 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
DVD E Vybornykh
D E Vybornykh
TMT N Moiseeva
T N Moiseeva
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
TGT V Gaponova
T V Gaponova
LEL V Esina
L V Esina
DND V Novikova
D V Novikova
Aim. To establish the features of the influence of anxiety and depressive disorders on treatment adherence, as well as to clarify the factors associated with it in hematologic malignancies patients. Materials and methods. The study included 117 patients: 51 men and 66 women, aged 19 to 67 years, with Hodgkin's lymphoma 88, acute lymphoblastic leukemia 16 and aplastic anemia 13 patients. Patients were examined by psychiatrist using the Brief Psychiatric Rating Scale, as well as some psychometric methods. Results. Anxiety-depressive spectrum disorders were detected in 36 (40.9%) patients with Hodgkin's lymphoma and 8 (50%) with acute lymphoblastic leukemia, in the aplastic anemia group there were three (23.1%) of such patients. It was found that the average adherence to treatment was in 2/3 of patients, low and high in the remaining 1/3 of patients. With medium and low adherence to treatment, the risk of adverse events increases by an average of 1.7 times. The adherence to treatment it is significantly higher in patients older than 45 years. Signs of depression that negatively correlated with adherence to treatment were pessimism and disruption of social ties. Adherence to treatment significantly positively correlates with the following types of attitudes towards the disease: anosognosic, hypochondriac and egocentric, and significantly negatively correlates with the following types of attitudes towards the disease: anxious, melancholic and dysphoric. Conclusion. Anxiety/depressive disorders contribute to reduced adherence of hematologic malignancies patients to treatment. Their correction and increased adherence should be carried out jointly by hematologists and mental health professionals.

28 May 2024 in Clinical Psychology and Special Education
Verified
Journal Article
Open access
PDF file
LEL.V. Esina
L.V. Esina
DVD.E. Vybornykh
D.E. Vybornykh
ERElena Rasskazova
Elena Rasskazova
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
EZE.E. Zvonkov
E.E. Zvonkov
AMAminat Umaraskhabovna Magomedova
Aminat Umaraskhabovna Magomedova
This study aims to investigate the relationship between of perceptions of illness and its causes, body and health, and illness behavior in relation to treatment adherence in patients with acute leukemia and lymphoma. We present one empirical study involving lymphoma patients (N=58) aged 19 to 64 years (M=41.22; SD=11.17), of whom 70.7% were female, and acute leukemia patients (N=51) aged 18 to 64 years (M=35.12; SD=12.90), of whom 54.9% were female. Participants completed the Illness Perception Questionnaire-Revised (IPQ-R), the Cognitions about body and health questionnaire (CABAH), the Scale for the Assessment of Illness Behavior (SAIB) and 4-item Morisky Medication Adherence Scale. The results suggest that patients with lymphoma are at risk for decreased treatment adherence compared to patients with acute leukemia. In acute leukemia, the targets of psychological work aimed at preventing reduced adherence to treatment are patients' perceptions of the psychological causes of the disease and their belief that healthy habits are not important for maintaining health, while in patients with lymphomas — uncertainty that immune problems could provoke the disease.

10 August 2019 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
MGMaria Gladysheva
Maria Gladysheva
TOTatiana Obukhova
Tatiana Obukhova
GAG. A. Alimova
G. A. Alimova
LSL. A. Shishigina
L. A. Shishigina
LGL. A. Grebenyuk
L. A. Grebenyuk
TMT. N. Moiseeva
T. N. Moiseeva
Aim.To evaluate the efficacy of DSP30 in combination with IL2 in cultivating blood cells/bone marrow/lymph nodes in chronic lymphocytic leukemia (CLL) patients to detect clonal abnormalities.Materials and methods.The study included 50 patients with CLL, all of whom underwent both chromosome banding analysis (CBA) (46 patients with DSP30+IL2 and LPS+TPA; 4 patients with only DSP30+IL2) and FISH with DNA probes to detect trisomy 12 and deletions of 13q14, 11q22 and 17p13.Results.Under cell cultivation with DSP30+IL2 and LPS+TPA, CBA was successfully performed in 41 (82 %) and 38 (83 %) patients. Chromosome aberrations were observed in 36 (72 %) and 15 (33%) cases, while a complex karyotype was detected in 13 (26%) and 5 (11%) cases, respectively. A significant difference was found between the number of metaphases with chromosomal abnormalities obtained by cultivation with DSP30+IL2 and LPS+TPA (V = 490.5, p < 0.05). CBA revealed balanced translocations in 6 patients, with the involvement of the IgH/14q324 locus being confirmed in 4 cases. Unbalanced translocations and various combinations of translocations were detected in 11 and 6 patients, respectively. In 5 cases, according to CBA, the results of 13q14, 11q22, 17p13 deletions identified by FISH were accompanied by balanced or unbalanced translocations in these loci. Unbalanced t(12;16)(q14;q23) — a case of partial trisomy — was detected only by CBA with DSP30+IL2.Conclusions.An abnormal karyotype was detected in CLL patients twice as more frequently under cultivation with DSP30+IL2 compared to LPS+TPA. CBA is an important method allowing the structure of chromosomal abnormalities to be specified and translocations to be identified. As a result, patients running the highest risk of CLL — those with a complex karyotype — can be singled out for selecting an optimal strategy of their management.

1 January 2016 in Terapevticheskii arkhiv
Verified
Journal Article
Closed access
LAL. S. Al-Radi
L. S. Al-Radi
TMT. N. Moiseeva
T. N. Moiseeva
HJH. L. Julhakyan
H. L. Julhakyan
KNK. I. Ntanishyan
K. I. Ntanishyan
AKAlla Mikhailovna Kovrigina
Alla Mikhailovna Kovrigina
VSV. G. Savchenko
V. G. Savchenko
To generalize hematologists' experience of the diagnosis and differential diagnosis of splenic red pulp lymphoma (SRPL). Eighty-seven splenic biopsy specimens taken from patients with different B-cell lymphoproliferative diseases were examined in the Hematology Research Center in 2013-2014. The diagnosis of SRPL was based on the morphological, immunohistochemical, immunophenotypic, and molecular examinations of the splenic biopsy specimens, blood and bone marrow (BM) tests in 4 (4.6%) cases. There was significant splenomegaly in all SRPL cases, lymphocytosis in 56 to 94% (leukocytes, 55 and 75·109/l in 2 cases), circulation of hairy lymphocytes with the phenotypes CD20+ (markedly), CD11c+/±, CD103+/± (weakly), LAIR-1+, CD25-, CD5-, CD10-, and CD23-, which did not contain tartate-resistant acid phosphatase, without BRAFV600E mutation, BM with insignificant lymphoid infiltration of CD20+, CD25-, Annexin 1-, and Cyclin D1-. The weight of the spleen averaged 3900 g (1450-9500 g); its tissue exhibited lymphoid infiltration of the red pulp with the phenotypes CD20+, DBA.44+, CD25-, Annexin1-, Cyclin D1-, CD103-, CD123-, CD27-, focal СD11c±, and TRAP±. Four patients (2 after splenectomy (SE) and 2 after SE and chemotherapy with cladribine and rituximab) are being followed up in remission. SRPL is a rare disease that should be presumed to be in significant splenomegaly and lymphocytosis with hairy lymphocytes, which have only some markers for classical hairy cell leukemia (HCL), in minor BM lesion. SE is the standard for diagnosis and treatment. The differential diagnosis of SRPL with HCL has clear criteria and that with HCL-v is undetected.